RxDoctor Payments Data

Eric Johnson, PA

Physician Assistant · Ogden, UTNPI 1841289600

Payments from drug & device makers

$4,772in general payments, 2019–2025

Across 275 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$887
  • AbbVie$870
  • Lilly USA, LLC$477
  • Pfizer$306
  • Biohaven Pharmaceutical Holding Company Ltd.$255
  • AstraZeneca$231
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,772 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$55,803
Medicare patients
206
Services billed
1,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$31,201
RybelsusSemaglutide25$24,107
OzempicSemaglutide25$23,856
TrulicityDulaglutide16$22,039
JardianceEmpagliflozin14$12,995
Soliqua 100-33Insulin Glargine/Lixisenatide13$12,797
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$9,823
XareltoRivaroxaban17$9,690
Emgality SyringeGalcanezumab-Gnlm11$7,287
JanuviaSitagliptin Phosphate13$6,970
AbrysvoRsv Vacc, Pref A And Pref B/Pf14$3,781
Albuterol Sulfate HfaAlbuterol Sulfate59$2,025
Esomeprazole Magnesium11$1,804
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,779
Omeprazole74$1,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$52$47,96350 claims
PfizerEliquis, Abrysvo$306$34,98152 claims
Boehringer IngelheimJardiance, Stiolto Respimat$89$22,81830 claims
Lilly USA, LLCTrulicity$477$22,03916 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$46$12,79713 claims
Johnson & JohnsonXarelto$57$9,69017 claims
MerckJanuvia$64$6,97013 claims
AbbVieSynthroid$870$81412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →